Abstract:Objective·To evaluate the role of 18F-MD-PSMA PET/CT in the initial stage of patients with moderate and high risk prostate cancer (PCa).Methods·A total of 67 patients with moderate and high risk PCa who were treated in Xinhua Hospital, Shanghai Jiao Tong University School of Medicine from September 2017 to June 2022 were initially staged by 18F-MD-PSMA PET/CT. Conventional imaging (CI), including multi-parameter magnetic resonance imaging (mp-MRI) and bone scintigraphy (BS), were performed within two weeks before 18F-MD-PSMA PET/CT. Twenty-five patients underwent 18F-FDG PET/CT at the same time. The sensitivity (SEN), specificity (SPEC), positive predictive value (PPV), negative predictive value (NPV) and accuracy (ACU) of 18F-MD-PSMA PET/CT in the initial stage were evaluated, and the results were compared with those of 18F-FDG PET/CT, mp-MRI and BS. The consistency of 18F-MD-PSMA PET/CT and CI in terms of primary lesion, regional lymph node metastasis and bone metastasis was evaluated by Kappa consistency test refering to the postoperative pathological T and N staging results and bone metastasis results of clinical follow-up. Kappa coefficient was calculated and compared.Results·Of the 67 patients with PCa, 38 patients underwent radical prostatectomy and had completed pathological data, with 27 patients undergoing regional lymphadenectomy and 1 patient undergoing expanded pelvic lymphadenectomy at the same time. The pathological results were obtained as gold standard. The detection rates of mp-MRI and 18F-MD-PSMA PET/CT in diagnosing intrathecal lesions were both 100%. The SENs in diagnosing bilateral intralobular lesions were 26.3% and 63.2%, respctively; the SPECs were both 75.0%.The Kappa consistency test showed that the consistency of 18F-MD-PSMA PET/CT in diagnosis of extracapsular extension (EPE), seminal vesicle invasion (SVI), and bladder neck invasion (BNI) was higher than that of mp-MRI. Fisher′s exact test showed that there were no statistically significant differences in SEN (P=0.226, P=0.491) and SPEC (P=1.000, P=0.342) between the two methods for diagnosing EPE and SVI, as well as SEN (P=1.000) for diagnosing BNI. In terms of diagnosis of lymph node metastasis, based on the analysis of lymph node numbers, the consistency between 18F-MD-PSMA PET/CT and pathological results was higher than that of mp-MRI (Kappa coefficients of 0.555 and 0.137, respectively). Fisher′s exact test showed that there were no statistically significant differences in SEN and SPEC between the two examination methods (P=0.562, P=0.829). Based on the patients, the consistency between 18F-MD-PSMA PET/CT and pathological results was higher than that of mp-MRI (Kappa coefficients of 0.850 and 0.313, respectively). There was no statistically significant difference in SEN between the two methods (P=1.000). In terms of diagnosis of bone metastasis, based on the analysis of bone lesion numbers, the consistency between 18F-MD-PSMA PET/CT and clinical follow-up results was higher than that of BS (Kappa coefficients of 0.500 and 0.299, respectively). Fisher′s exact test showed that there was no statistically significant difference in SEN between the two methods (P=0.219). Based on the patients, the consistency between 18F-MD-PSMA PET/CT and clinical follow-up results was higher than that of BS (Kappa coefficients of 0.953 and 0.766, respectively). There was no statistically significant difference in SEN between the two methods (P=1.000). The risks of 21 patients (31.3%) were increased after 18F-MD-PSMA PET/CT detection, with 1 patient (1.5%) decreasing. The initial stage of 32 cases (47.8%) were changed after 18F-MD-PSMA PET/CT detection, with 27 cases (40.3%) upstaged and 5 cases (7.5%) downstaged.Conclusion·18F-MD-PSMA PET/CT is superior to CI in the diagnosis of bilateral intralobular lesions, EPE, SVI, regional lymph node metastasis and bone metastasis in intermediate and high risk PCa, and on this basis, the diagnosis of clinical stage and metastatic status of some patients has been changed.

MP20-15 COMPARISON BETWEEN 68 GA-LABELLED PSMA AND 18 F-FDG PET/CT IN THE DIAGNOSTIC VALUE OF CLEAR CELL RENAL CELL CARCINOMA

MP36-02 DIAGNOSTIC VALUE OF 68 GA-LABELLED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) PET/CT IMAGING FOR RENAL CELL CARCINOMA

MP80-12 GREAT CLINICAL VALUE OF 68GA-PSMA PET/CT IMAGING FOR CLEAR CELL RENAL CELL CARCINOMA

Special Issue “the Advance of Solid Tumor Research in China”: 68ga‐psma‐11 PET/CT for Evaluating Primary and Metastatic Lesions in Different Histological Subtypes of Renal Cell Carcinoma

Head-to-head Comparison of [68Ga]ga-P16-093 and 2-[18F]FDG PET/CT in Patients with Clear Cell Renal Cell Carcinoma: a Pilot Study

Value of [68Ga]ga-Nym046 PET/CT, in Comparison With18f-Fdg PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma

Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study

Head-to-head comparisons of enhanced CT, <SUP>68</SUP>Ga-PSMA-11 PET/CT and <SUP>18</SUP>F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study

Intra-Individual Comparison Of 18f-Psma-1007 And 18f-Fdg Pet/Ct In The Evaluation Of Patients With Prostate Cancer

Comparison between 68Ga-PSMA-11 PET/CT and multiparametric magnetic resonance imaging in patients with biochemically recurrent prostate cancer following robot-assisted radical prostatectomy

Clinical Value of 68Ga-Psma-11 PET/CT in the Diagnosis of Castration-Resistant Prostate Cancer

[ 68 Ga]Ga‑LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-[ 18 F]FDG/[ 68 Ga]Ga-PSMA PET/CT

Comprehensive Evaluation of 68Ga-Psma-11 PET/CT Parameters for Discriminating Pathological Characteristics in Primary Clear-Cell Renal Cell Carcinoma

Inconsistent Detection of Metastatic Non-clear Cell Renal Cell Carcinoma by PSMA-targeted F-18-DCFPyL PET/CT

[18F]AlF-PSMA-11 PET in diagnosing prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-11 PET and an exploration of dual-phase scanning

The Added Value of 18F-FDG PET/CT Compared with 68Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer

18F-FDG PET Is Not Inferior to 68Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study

Role of 18F-MD-PSMA PET/CT in initial stage of intermediate and high risk prostate cancer

Comparative study in diagnostic value of 68Ga-PSMA-617 PET/CT and multi-parameter MRI for primary prostate cancer

Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study

The added value of 18F-FDG PET/CT compared to 68Ga-PSMA PET/CT in patients with castration-resistant prostate cancer